CELC — Celcuity Inc.

Celcuity (CELC) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Loss: $52.8 million ($0.97 per share), compared to a net loss of $37 million ($0.86 per share) in Q1 2025.
• Non-GAAP Adjusted Net Loss: $46.8 million ($0.86 per share), up from $34.7 million ($0.81 per share) year-over-year.
• R&D Expenses: $33.1 million, an increase from $29.8 million in the prior year, driven by higher employee and manufacturing costs.
• SG&A Expenses: $17.4 million, significantly up from $6.3 million, primarily due to increased commercial headcount and launch-related activities.
• Net Cash Used in Operating Activities: $55.1 million, compared to $35.9 million in Q1 2025.
• Cash Position: $387.1 million in cash, cash equivalents, and short-term investments, expected to fund operations through 2027.

2. Strategic Updates and Business Highlights

• Gedatolisib Development: Positive results from the PIK3CA mutant cohort of the Phase III VIKTORIA-1 study, positioning gedatolisib as a potential new standard of care for HR-positive/HER2-negative advanced breast cancer.
• Expansion of Clinical Trials: Initiated VIKTORIA-2 trial to evaluate gedatolisib as a first-line treatment for both endocrine-sensitive and endocrine-resistant patients.
• Subcutaneous Formulation: Development of a subcutaneous formulation of gedatolisib is underway, with a patent application submitted.
• Commercial Readiness: All oncology sales specialists have been hired, with extensive outreach to payers and oncologists ongoing in preparation for a potential launch.

3. Forward Guidance and Outlook

• FDA Approval: Anticipated approval of gedatolisib by July 17, 2026, with plans for a supplemental NDA based on new data from the VIKTORIA-1 study.
• Market Potential: Estimated total addressable market for gedatolisib in the second-line setting exceeds $5 billion annually, with potential peak revenue of $2.5 billion.
• Clinical Trial Timelines: Expecting top-line data from VIKTORIA-2 by the end of 2028 for endocrine-resistant patients and by 2030 for endocrine-sensitive patients.

4. Bad News, Challenges, or Points of Concern

• Increased Losses: The rise in net losses and operating cash usage raises concerns about financial sustainability without revenue from gedatolisib.
• Regulatory Risks: Uncertainty surrounding FDA approval and potential delays in the PDUFA timeline could impact commercialization plans.
• Competitive Landscape: The presence of other PIK3CA inhibitors in development may pose challenges for market share and pricing strategies.

5. Notable Q&A Insights

• FDA Interactions: Management refrained from disclosing detailed interactions with the FDA but indicated no issues that would delay the PDUFA date.
• Subcutaneous Formulation: Questions on the timeline and regulatory process for the subcutaneous formulation were addressed, emphasizing the need for equivalence studies.
• Commercial Readiness: The team expressed confidence in their preparedness for a potential launch, citing extensive groundwork laid with payers and oncologists.
• Competitive Positioning: Management highlighted the differentiation of gedatolisib from single-target inhibitors, asserting its potential for superior efficacy in treating advanced breast cancer.

Overall, Celcuity is making significant strides in its clinical development and commercial preparations for gedatolisib, despite facing financial losses and competitive pressures. The upcoming ASCO meeting and FDA decision are pivotal for the company's future trajectory.